The Journal of Practical Medicine >
Construction of a predictive model for left ventricular hypertrophy in female patients with essential hypertension based on plasma aldosterone and clinical parameters
Received date: 2025-08-26
Online published: 2025-12-25
Objective To investigate the role of plasma aldosterone (ALD) in the development of left ventricular hypertrophy (LVH) in women with essential hypertension (EH), and to develop a predictive model incorporating ALD and clinical parameters to improve early detection and risk stratification of LVH. Methods A total of 200 female patients with EH were enrolled and classified into the LVH group (n = 104) and the NLVH group (n = 96). Clinical characteristics, laboratory parameters, ALD levels, and ambulatory blood pressure monitoring (ABPM) data were systematically collected. Spearman′s rank correlation coefficient was used to evaluate the association between ALD levels and left ventricular mass index (LVMI). Multivariate logistic regression analyses were conducted to identify independent predictors of LVH, with three models constructed: Model 1 included ALD alone; Model 2 adjusted for ALD, diabetes, 24-hour systolic blood pressure (24hSBP), nighttime SBP (nSBP), blood pressure load (BPL), and nighttime blood pressure decline (NBD); Model 3 further incorporated ALD, diabetes, blood glucose (BG), NT-proBNP, 24hSBP, 24-hour diastolic blood pressure (24hDBP), and arterial stiffness index (ASI). The discriminative performance of each model was assessed using receiver operating characteristic (ROC) curve analysis, with internal validation performed to ensure robustness. Results Compared with the NLVH group, the LVH group exhibited a higher prevalence of diabetes and significantly elevated levels of BG, NT-proBNP,24hSBP, 24hDBP, and ALD, along with a smaller NBD (all P < 0.05). Spearman′s rank correlation analysis revealed a statistically significant positive correlation between ALD and LVMI (r = 0.478, P < 0.001). In multivariate logistic regression analysis, ALD remained an independent predictor of LVH (OR = 1.014, P = 0.002), after adjusting for other significant variables including diabetes, BG, NT-proBNP, 24hSBP, 24hDBP, and ASI. The combined predictive model (Model 3) demonstrated the highest discriminative ability (AUC = 0.852; Hosmer?Lemeshow test P > 0.05), surpassing models based on single predictors. Internal bootstrap validation confirmed excellent calibration and robustness of the model′s predictive performance. Conclusions Elevated plasma aldosterone concentration is an independent risk factor for LVH in women with essential hypertension. A multimodal predictive model that integrates aldosterone levels, clinical parameters, and dynamic blood pressure measurements can substantially enhance the accuracy of LVH prediction, offering a reliable approach for individualized management and early intervention in female patients with hypertension.
Yexiang MA , Long AI , Yu HUANG , Yanwen GAO , Jing. YU . Construction of a predictive model for left ventricular hypertrophy in female patients with essential hypertension based on plasma aldosterone and clinical parameters[J]. The Journal of Practical Medicine, 2025 , 41(24) : 3904 -3913 . DOI: 10.3969/j.issn.1006-5725.2025.24.015
| [1] | NCD RISK FACTOR COLLABORATION (NCD-RISC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021, 398(10304): 957-980. |
| [2] | ZHANG L M, SHI Y Z, ZHOU B H, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18:Findings from six rounds of a national survey[J]. BMJ, 2023, 380: e071952. doi:10.1136/bmj-2022-071952 |
| [3] | 《中国心血管健康与疾病报告》编写组. 中国心血管健康与疾病报告2024概要[J]. 中国循环杂志, 2025, 40(6): 521-559. |
| [4] | XU Y M, WANG W L, LIU Y H, et al. The burden of hypertension in China: The China Hypertension Survey[J]. J Hypertens, 2022, 40(2): 215-223. |
| [5] | YEO T M, CHIN W L C, SEAH C W A, et al. Global Prevalence of Myocardial Fibrosis among Individuals with Cardiometabolic Conditions: A Systematic Review and Meta-Analysis[J]. Eur J Prev Cardiol, 2025, 32(12):1077-1091. doi:10.1093/eurjpc/zwaf083 |
| [6] | ?OR?EVI? D B, KORA?EVI? G P, ?OR?EVI? A D, et al. Hypertension and left ventricular hypertrophy[J]. J Hypertens, 2024, 42(9): 1505-1515. doi:10.1097/hjh.0000000000003774 |
| [7] | DUMITRESCU M, CONSTANTIN A, NEMECZ A M, et al. Hypertension induces compensatory left ventricular hypertrophy by a mechanism involving gap junction lateralization and overexpression of CD36, PKC and MMP-2[J]. Rom J Morphol Embryol, 2021, 62(3): 713-721. doi:10.47162/rjme.62.3.08 |
| [8] | 刘旭帮,魏娟玲. 高血压患者左心室肥厚与血清脂联素和炎性因子水平的关系[J]. 中国热带医学,2015,15(7):875-877. |
| [9] | 黄艺霖,李爽,贺正庸,等. 肠道菌群在高血压治疗中的研究进展[J]. 实用医学杂志,2025,41(19):3129-3134. |
| [10] | WU S L, FENG X Y, ZHENG H Y, et al. Sex-Specific Association of Left Ventricular Hypertrophy With Cardiovascular Events in High-Risk of Cardiovascular Disease Population: Findings From the Sub-Cohort of China PEACE Million Persons Project[J]. J Clin Hypertens (Greenwich), 2025, 27(5): e70072. doi:10.1111/jch.70072 |
| [11] | 崔晓通, 周京敏, 徐亚妹, 等. 左心室肥厚诊断与治疗(复旦中山规范)[J]. 上海医学, 2024, 47(2): 65-73. |
| [12] | CANCIELLO G, PICCOLO R, IZZO R, et al. Sex-Related Differences in Left Ventricular Geometry Patterns in Patients With Arterial Hypertension[J]. JACC Adv, 2024, 3(10): 101256. doi:10.1016/j.jacadv.2024.101256 |
| [13] | GHAZI L, BELLO N A. Hypertension in Women Across the Lifespan[J]. Curr Atheroscler Rep, 2021, 23(8): 43. doi:10.1007/s11883-021-00941-4 |
| [14] | 王梦卉, 王梦茹, 骆秦, 等. 高血压及原发性醛固酮增多症患者血清钾及低钾血症与心电图左心室肥大的关系[J]. 中华诊断学电子杂志, 2024, 12(1): 18-24. |
| [15] | 中国高血压防治指南修订委员会, 高血压联盟(中国, 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700. |
| [16] | NIEWIARA ?, KLECZY?SKI P, GUZIK B, et al. Prevalence of coronary microcirculatory dysfunction in patients with chronic coronary syndromes and moderate coronary stenosis[J]. Kardiol Pol, 2025, 83(4): 465-473. doi:10.33963/v.phj.104620 |
| [17] | BOLLATI M, LOPEZ C, BIOLETTO F, et al. Atrial Fibrillation and Aortic Ectasia as Complications of Primary Aldosteronism: Focus on Pathophysiological Aspects[J]. Int J Mol Sci, 2022, 23(4): 2111. doi:10.3390/ijms23042111 |
| [18] | 丁美琳,徐敏,吴芳,等. 醛固酮诱导的氧化应激损伤内皮祖细胞介导的血管内皮修复功能[J]. 中山大学学报(医学版),2018,39(6):818-826. |
| [19] | AL-HASHEDI E M, ABDU F A. Aldosterone Effect on Cardiac Structure and Function[J]. Curr Cardiol Rev, 2024, 20(4): e290224227534. doi:10.2174/011573403x281390240219063817 |
| [20] | SAKABE M, THOMPSON M, CHEN N, et al. Inhibition of β1-AR/Gαs signaling promotes cardiomyocyte proliferation in juvenile mice through activation of RhoA-YAP axis[J]. Elife, 2022, 11: e74576. doi:10.7554/elife.74576 |
| [21] | YANG J H, YOUNG M J, COLE T J, et al. Mineralocorticoid receptor signalling in primary aldosteronism[J]. J Endocrinol, 2023, 259(1): e220249. doi:10.1530/joe-22-0249 |
| [22] | IMPROTA-CARIA A C, ARAS M G, NASCIMENTO L, et al. MicroRNAs Regulating Renin-Angiotensin-Aldosterone System, Sympathetic Nervous System and Left Ventricular Hypertrophy in Systemic Arterial Hypertension[J]. Biomolecules, 2021, 11(12): 1771. doi:10.3390/biom11121771 |
| [23] | AL ALI H S, RODRIGO G C, LAMBERT D G. Signalling pathways involved in urotensin II induced ventricular myocyte hypertrophy[J]. PLoS One, 2025, 20(1): e0313119. doi:10.1371/journal.pone.0313119 |
| [24] | YE C Y, WANG T T, GONG J Y, et al. Development of a nomogram for screening the risk of left ventricular hypertrophy in Chinese hypertensive patients[J]. J Clin Hypertens (Greenwich), 2021, 23(6): 1176-1185. doi:10.1111/jch.14240 |
| [25] | YANG L X, YAN L N, QIU L S, et al. Preoperative predictive indicators for resolution of hypertension in patients with unilateral primary aldosteronism: Development of a nomogram model[J]. Langenbecks Arch Surg, 2025, 410(1): 52. doi:10.1007/s00423-025-03615-w |
| [26] | 黄慧, 苏金虎, 吴冰. 不同降压水平对老年高血压患者复合心血管事件的影响[J]. 实用医学杂志, 2023, 39(17): 2225-2229. |
/
| 〈 |
|
〉 |